The Global Market for Prostate Cancer Therapeutics is Projected to Reach US$13.1 Billion by 2022
Rising Prevalence of the
Disease & Unmet Medical Needs Drive the Prostate Cancer Therapeutics
Market, According to a New Report by Global Industry Analysts,
Inc.
GIA launches comprehensive analysis of industry
segments, trends, growth drivers, market share, size and demand forecasts on
the global Prostate Cancer Therapeutics market. The global market for Prostate
Cancer Therapeutics is projected to reach US$13.1 billion by 2022, driven by the increasing
incidence of prostate cancer globally and the resulting demand for novel affordable
therapies that offer high efficacy, low toxicity and longer patient survival.
Prostate cancer is the most common form of cancer
affecting men, with about 180,890 new cases diagnosed in 2016, as per the
American Cancer Society’s estimates. Along with the increasing prevalence of
prostate cancer around the world, factors driving the prostate cancer
therapeutics market include the rising geriatric population base, and growing
demand for novel therapies. Various products are being researched that offer
increased survival time without disease progression, and also lesser toxicity
and lower costs. These investigational [prostate cancer therapeutic solutions offer
profitable market opportunities over the near and long term. Targeted prostate
cancer therapies, which work by targeting cancer cells in specific, leaving
healthy cells undamaged, is rapidly taking over chemotherapy. First-generation targeted therapies, comprising mainly of
monoclonal antibodies, are not favored by patients due to inherent
disadvantages. Second-generation targeted therapies, which are orally
bioavailable, are expected to drive the market into the future with desirable
features, such as superior therapeutic efficacy, optimum dosing, and ability to
fight drug resistance.
Hormone therapy, also called androgen deprivation
therapy (ADT), represents the leading treatment modality for prostate cancer
with high survival rates among patients. The once-daily oral medication, Zytiga (abiraterone acetate) used in combination with
prednisone, has become the gold standard for prostate cancer therapy since
2011. Other leading drugs, Xtandi, Lupron/Leuplin, and Zoladex, are also
anti-androgens and LHRH analogs. Other therapies like immunotherapy are
witnessing rapid growth. While Provenge® developed by Dendreon is already in
the market, other immunotherapies such as ProscaVax and ADXS-PSA +
pembrolizumab are being investigated for treating metastatic,
castration-resistant prostate cancer. Factors restraining market growth include
high treatment costs, low patient compliance owing to complicated treatment
methods, multiple drug resistance, and also clinical trial challenges and
stringent regulatory approvals required for novel therapeutics.
As
stated by the new market research report on Prostate Cancer Therapeutics, the United States
represents the largest market worldwide. Developing markets led by Asia-Pacific,
ranks as the fastest growing market with a CAGR of 12.1% over the analysis
period. The growth in emerging economies is supported by growing population
base, rapid urbanization, changing lifestyle factors that raise the risk of
cancer, developing healthcare infrastructure, increasing per capita healthcare
spending among the expanding base of middle class population and rising patient
awareness about the disease and available treatment options.
Major players in the market include AbbVie Inc., Allergan
plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers
Squibb Company, Debiopharm Group, Dendreon Pharmaceuticals LLC, Endo
Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Genentech Inc.,
GlaxoSmithKline Plc., Janssen Biotech Inc., Myovant Sciences Ltd., Novartis AG,
Pfizer Inc., Progenics Pharmaceuticals Inc., Sanofi S.A., Spectrum
Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and TOLMAR
Pharmaceuticals Inc.
The research report titled "Prostate Cancer Therapeutics:
A Global Strategic Business Report" announced by Global Industry Analysts Inc.,
provides a comprehensive review of market trends, growth drivers, mergers and
acquisitions, and other strategic industry activities of major companies
worldwide. The report provides market estimates and projections for geographic
markets, such as the US, Canada, Europe (France, Germany, Italy, UK, Spain, and
Rest of Europe), and Rest of World. Therapy segments analyzed for the market
include Hormone Therapy and Others (which include Radiation Therapy,
Immunotherapy, and Chemotherapy).
For
enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.
To
connect with us, visit our LinkedIn page.
Global Industry
Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.
Comments
Post a Comment